J Stroke.  2024 May;26(2):335-338. 10.5853/jos.2024.00584.

Left Atrial Mechanical Dysfunction Is Associated With Atrial Fibrillation and Recurrent Stroke After Cryptogenic Stroke

• Raco J
• Shah R
• Farbaniec M
• Norby FL
• Mann M
• Gonzalez MD
• Naccarelli GV
• Maheshwari A

• KMID: 2556055
• DOI: http://doi.org/10.5853/jos.2024.00584

Figure

• 

  Figure 1. Association of left atrial mechanical dysfunction with atrial fibrillation detected after cryptogenic stroke. (A) Restricted cubic spline with knots at 10%, 50%, and 90%. Adjustments made for age, sex, hypertension, coronary artery disease, stroke or transient ischemic attack, peripheral artery disease, diabetes, carotid artery stenosis, congestive heart failure, and left atrial volume index. (B) Unadjusted cumulative incidence of atrial fibrillation. Categories of left atrial emptying fraction (LAEF) selected by whole number corresponding to the bottom 10%, middle 30%, and remaining 60%.

Reference

References

1. Edwards JD, Healey JS, Fang J, Yip K, Gladstone DJ. Atrial cardiopathy in the absence of atrial fibrillation increases risk of ischemic stroke, incident atrial fibrillation, and mortality and improves stroke risk prediction. J Am Heart Assoc. 2020; 9:e013227.

2. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017; 48:867–872.

3. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018; 378:2191–2201.

4. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019; 380:1906–1917.

5. Jiang H, Tan SY, Wang JK, Li J, Tu TM, Tan VH, et al. A metaanalysis of extended ECG monitoring in detection of atrial fibrillation in patients with cryptogenic stroke. Open Heart. 2022; 9:e002081.

6. Kamel H. Primary results of the atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke (ARCADIA) randomized trial. Proceedings of the 9th European Stroke Organisation Conference; 2023 May 24-26; Munich, Germany. Basel: European Stroke Organisation, 2023.

7. Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med. 2024; 390:107–117.

8. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007; 4:e297.

9. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021; 52:e364–e467.

10. Maheshwari A, Norby FL, Inciardi RM, Wang W, Zhang MJ, Soliman EZ, et al. Left atrial mechanical dysfunction and the risk for ischemic stroke in people without prevalent atrial fibrillation or stroke: a prospective cohort study. Ann Intern Med. 2023; 176:39–48.